Zobrazeno 1 - 10
of 24
pro vyhledávání: '"HF Marlow"'
Publikováno v:
British journal of clinical pharmacology. 29(5)
1. We examined the relationship between the contractile state of the left ventricle and the plasma concentration of xamoterol in patients with ischaemic heart failure. 2. Identical studies were conducted in 14 middle-aged (all male; mean age 51.3 yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c0f5bc8fcfdfd1b90b236f1c771a84
https://pubmed.ncbi.nlm.nih.gov/2140946
https://pubmed.ncbi.nlm.nih.gov/2140946
Publikováno v:
British Journal of Clinical Pharmacology. 28:67S-69S
Xamoterol has been shown in large, double-blind studies to produce benefit in patients with heart failure. Ischaemic heart disease is the commonest cause of heart failure in the Western World and many patients with heart failure also have angina pect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b5bb4fe569391963b38aaacadeed3c
https://doi.org/10.1111/j.1365-2125.1989.tb03576.x
https://doi.org/10.1111/j.1365-2125.1989.tb03576.x
Autor:
HF Marlow
Publikováno v:
British journal of clinical pharmacology. 28
1 Xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587), a β1-adrenoceptor partial agonist, improves both systolic and diastolic function in heart failure patients. 2 Double-blind, randomised studies comparing xamoterol with placebo showed that th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20291c1c2280ee665e23776b3e6c6aba
https://pubmed.ncbi.nlm.nih.gov/2572251
https://pubmed.ncbi.nlm.nih.gov/2572251
Publikováno v:
British journal of clinical pharmacology. 28
The effects of age and renal function on the pharmacokinetics and plasma concentrations of xamoterol were examined. Peak and steady state concentrations were higher in older patients, but this was due to deterioration of renal function rather than to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6019778dd60dc7b2ad1dacd44d2c2da8
https://pubmed.ncbi.nlm.nih.gov/2572257
https://pubmed.ncbi.nlm.nih.gov/2572257
Publikováno v:
British Journal of Clinical Pharmacology. 7:429P-430P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c486b6e507dea04f64e2fe1f999686
https://doi.org/10.1111/j.1365-2125.1979.tb00974.x
https://doi.org/10.1111/j.1365-2125.1979.tb00974.x
Autor:
Fallowfield JM, Marlow HF
Publikováno v:
BMJ (Clinical research ed.) [BMJ] 1996 Dec 07; Vol. 313 (7070), pp. 1486.
Autor:
Marlow HF; Medical Affairs Department, Zeneca Pharmaceuticals, Macclesfield, UK.
Publikováno v:
Cardiology [Cardiology] 1994; Vol. 85 Suppl 1, pp. 102-12.
Autor:
Marlow HF; Medical Research Department, ICI Pharmaceuticals, Alderley Park, Cheshire., Hine FL, Snow HM, Pouleur H, Rousseau MF
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 1990 May; Vol. 29 (5), pp. 511-8.
Publikováno v:
European heart journal [Eur Heart J] 1990 Apr; Vol. 11 Suppl A, pp. 62-4.
Autor:
James MA; Department of Cardiology, Bristol Royal Infirmary., Papouchado M, Channer KS, Jones JV, Marlow HF, Bastain W, Barker NP, Harry JD, Wardleworth AG
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 1990 Apr; Vol. 29 (4), pp. 447-53.